Physician profile
Lemuel Lopez
NPI 1386323913
$633.95
in general payments reported to CMS, 2019-2025
14 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $195 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $89.57 | 2025 | Rexulti |
| Lilly USA, LLC | $86.93 | 2024-2025 | Jardiance, Mounjaro |
| Abbvie INC. | $85.73 | 2024-2025 | |
| Novo Nordisk INC | $77.70 | 2024-2025 | Rybelsus, Ozempic |
| Acella Pharmaceuticals, LLC | $48.48 | 2024-2025 | NP Thyroid 60 |
| Glaxosmithkline, LLC. | $41.67 | 2025 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.80 | 2025 | Caplyta |
| Shield Therapeutics INC | $34.54 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.63 | 2025 | |
| X4 Pharmaceuticals, INC. | $23.69 | 2024 | Xolremdi |
| Radius Health, INC. | $21.92 | 2025 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $21.32 | 2025 | Journavx |
| Verrica Pharmaceuticals INC. | $19.17 | 2024 | Ycanth |
| Paratek Pharmaceuticals, INC. | $17.80 | 2025 | Nuzyra, Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lemuel Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.